cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Three new phase 3 REIMAGINE
Description
Reduced rates of carbohydrate digestion and absorption likely accounted for these effects
Exclusion criteria were symptomatic brain metastases, uncontrolled pleural or peritoneal effusions, and inability to interrupt non-steroidal anti-inflammatory drugs

You will draw up the prescribed amount with the provided insulin needle and syringe, then inject subcutaneously

And dont place one patch on top of another